back to top
HomeMarketKaufman's MAK Capital sells over $16 million in Agilysys inventory By

Kaufman's MAK Capital sells over $16 million in Agilysys inventory By


Michael A. Kaufman, by means of entities affiliated with MAK Capital, has bought a good portion of Agilysys Inc. (NASDAQ:) inventory, totaling over $16 million. The transactions occurred over three separate days, with shares bought at costs starting from $96.43 to $99.35.

The gross sales have been executed beneath a prearranged 10b5-1 buying and selling plan, which permits firm insiders to promote shares at predetermined occasions to keep away from accusations of insider buying and selling. In accordance with the plan dated January 25, 2024, between MAK Capital One LLC and BTIG, LLC, a complete of 166,712 shares of Agilysys Inc. have been bought.

The primary transaction passed off on June 21, the place 61,035 shares have been bought at a median worth of $96.43 per share. This was adopted by a sale of 45,000 shares on June 24, at a median worth of $98.48 per share. The ultimate transaction on June 25 noticed 60,677 shares bought at a median worth of $99.35 per share. The full worth of the shares bought amounted to roughly $16,345,604.

MAK Capital One LLC acts because the funding supervisor for MAK Capital Fund LP, and Mr. Kaufman is the managing member of MAK Capital. Each entities could also be deemed to not directly beneficially personal the shares held by MAK Fund. Nonetheless, they’ve disclaimed such useful possession, besides to the extent of their pecuniary curiosity.

The SEC submitting additionally clarifies that the reported costs are weighted averages and that the reporting individuals will present full data relating to the variety of shares bought at every worth upon request by the Issuer or the SEC.

This substantial sale by a key affiliate of an Agilysys director suggests important portfolio changes by MAK Capital, though the explanations behind the sale haven’t been disclosed. Buyers and analysts usually monitor insider transactions for insights into firm well being and administration sentiment.

In different latest information, Agilysys Inc. has been the focal point within the funding world resulting from its spectacular monetary efficiency and constructive outlooks from analysts. The corporate reported record-breaking revenues for the ninth consecutive quarter, with a 17.6% improve from the prior yr, reaching $62.2 million within the fourth quarter of fiscal yr 2024. Full fiscal yr income additionally set a document at $237.5 million, up 19.9% from the earlier yr. On prime of this, Agilysys tasks a income progress of 16% to 18% for fiscal 2025, anticipating revenues between $275 million to $280 million.

Agilysys additionally secured important offers not too long ago, together with an settlement with Marriott Worldwide (NASDAQ:) to combine the Agilysys Golf product suite into Marriott’s lodges throughout North America, the Caribbean, and Latin America. One other main growth was the corporate’s initiation with an Outperform ranking by William Blair, which was based mostly on Agilysys’s strong gross sales momentum and potential for enlargement.

As well as, Needham maintained a Purchase ranking on Agilysys and elevated the value goal to $125 from $100. Oppenheimer additionally confirmed confidence within the firm by elevating its worth goal from $95.00 to $100.00. These latest developments mirror a promising future for Agilysys, with the corporate anticipating at the least 27% progress in subscription income.

InvestingPro Insights

As Agilysys Inc. (NASDAQ:AGYS) experiences notable insider buying and selling exercise, buyers could discover further context by means of real-time metrics and InvestingPro Suggestions. Michael A. Kaufman’s sizable inventory sale coincides with a interval the place AGYS is buying and selling close to its 52-week excessive, with a worth 96.64% of that peak, reflecting a strong year-over-year worth whole return of 51.83%. This efficiency aligns with the InvestingPro Tip highlighting AGYS’s sturdy return during the last yr.

InvestingPro Knowledge additional reveals that AGYS has a market capitalization of $2.74 billion and is buying and selling at a Worth / Earnings (P/E) ratio of 30.39, which adjusts to 32.25 for the final twelve months as of This autumn 2024. The corporate’s income progress can also be notable, with a 19.89% improve during the last twelve months as of This autumn 2024, indicating a wholesome enlargement in its monetary efficiency.

One InvestingPro Tip that buyers ought to think about is that AGYS holds extra cash than debt on its stability sheet, which can present a cushion in opposition to market volatility and supply monetary flexibility for future investments or operations. Moreover, analysts predict the corporate can be worthwhile this yr, which is a constructive sign for potential buyers.

To achieve additional insights and entry extra detailed evaluation, readers can discover further InvestingPro Suggestions for AGYS at At present, there are 15 further suggestions out there, which might present a complete outlook on the corporate’s monetary well being and inventory efficiency. For these fascinated about a yearly or biyearly Professional and Professional+ subscription, use the coupon code PRONEWS24 to obtain an extra 10% off.

This text was generated with the assist of AI and reviewed by an editor. For extra data see our T&C.


Please enter your comment!
Please enter your name here



Citi raises AT&T inventory goal, maintains Purchase on progress technique By

Citi up to date its outlook on AT&T (NYSE: T), rising the inventory's value goal from $20.00 to $21.00 whereas reiterating a Purchase ranking. This...

ITV shares down after income steering minimize in first-half interim outcomes

Picture supply: Getty Pictures ITV (LSE :ITV) shares are buying and selling down virtually...

Linuscoins Launches Group Grants Program – Blockchain Information Website

Linuscoins is happy to announce the launch of its Group Grants Program, a brand new initiative designed to assist progressive initiatives and startups throughout the...

AbbVie Q2 2024 adj. revenue drops regardless of larger revenues; outcomes beat | AlphaStreet

Specialty biopharmaceutical firm AbbVie, Inc. (NYSE: ABBV) Thursday introduced second-quarter 2024 monetary outcomes, reporting a decline in adjusted earnings and a rise in revenues. The...

Most Popular